A Randomized, Double-blind, Dose-escalation Clinical Trial of the Safety, Reactogenicity and Immunogenicity of MTBVAC Compared to BCG Vaccine SSI, in Newborns Living in a Tuberculosis Endemic Region With a Safety Arm in Adults
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 01 Jul 2017
At a glance
- Drugs MTBVAC (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Biofabri
- 26 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 10 Jun 2017 Biomarkers information updated
- 23 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.